Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Dermatol. Sep 2, 2022; 10(2): 10-16
Published online Sep 2, 2022. doi: 10.5314/wjd.v10.i2.10
Published online Sep 2, 2022. doi: 10.5314/wjd.v10.i2.10
Connection between dermatomyositis and montelukast sodium use: A case report
Mohammed H Aly, Abdelgaffar Mohammed, Department of Internal Medicine, Security Forces Hospital, Makkah 21599, Saudi Arabia
Abdulrahman A Alshehri, Department of Rheumatology, Security Forces Hospital, Makkah 21599, Saudi Arabia
Murouj Adnan Almaghrabi, Malek M Alharbi, College of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia
Author contributions: Aly MH, Alshehri AA and Mohammed A have reviewed the literature and contributed to manuscript drafting; Almaghrabi MA analyzed and interpreted the imaging findings and contributed to manuscript drafting; Alharbi MM was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.
Informed consent statement: The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given consent for his images and other clinical information to be reported in the Journal. The patient understands that his names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Murouj Adnan Almaghrabi, MBBS, Doctor, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, 8WCQ+4RM, Makkah 24382, Saudi Arabia. murouj.a.a@gmail.com
Received: March 6, 2022
Peer-review started: March 6, 2022
First decision: April 13, 2022
Revised: April 22, 2022
Accepted: July 26, 2022
Article in press: July 26, 2022
Published online: September 2, 2022
Processing time: 178 Days and 6.6 Hours
Peer-review started: March 6, 2022
First decision: April 13, 2022
Revised: April 22, 2022
Accepted: July 26, 2022
Article in press: July 26, 2022
Published online: September 2, 2022
Processing time: 178 Days and 6.6 Hours
Core Tip
Core Tip: Even though montelukast is widely used and believed to be a safe drug for managing several conditions, the present case report brings to light the possibility of adverse effects of montelukast. Especially in such a rare and serious complication of montelukast, physicians must be aware of the presentation of dermatomyositis, the diagnostic modalities, and the best treatment options for the patients, as the prompt diagnosis will prevent further complications progression of the condition.